Search clinical trials for: hormone receptor positive breast cancer

Total 148494 results

Western Regional Medical Center

Terminated

Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Neohttp)

HER2-positive Breast Cancer | ER-positive Breast Cancer

United States
Fudan University

Terminated

Bicalutamide as A Treatment in AR-positive Metastatic Triple-Negative Breast Cancer (mTNBC) Patients

Breast Cancer

China
GlaxoSmithKline

Withdrawn

Phase II Study Evaluating Exemestane Alone Or In Combination With Pazopanib In Postmenopausal Women With Hormone Receptor Positive Breast Cancer

Hormone-receptor Positive Breast Cancer

United States
Masonic Cancer Center, University of Minnesota

Terminated

Phase II of Naltrexone in Hormone-Refractory Metastatic Breast Cancer

Breast Cancer

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Analyzing a New Mechanism in Response to Tamoxifen Therapy in Breast Cancer Patients

Breast Cancer

United States
National Cancer Institute (NCI)

Completed

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast Carcinoma

United States
University of California, San Francisco
National Cancer Institute (NCI)

Completed

Effects of Chemotherapy on the Brain in Women With Newly Diagnosed Early-Stage Breast Cancer

Breast Cancer | Fatigue | Neurotoxicity | Cognitive/Functional Effects | Psychosocial Effects of Cancer and Its Treatment | Long-term Effects Secondary to Cancer Therapy in Adults | Chemotherapeutic Agent Toxicity

United States
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
The Netherlands Cancer Institute

Terminated

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Breast Cancer

Netherlands
Novartis Pharmaceuticals

Completed

Optimal Duration of Pre-operative Treatment With Letrozole and to Correlate Clinical Efficacy With Appropriate Surrogate Markers

Breast Cancer
National Cancer Institute (NCI)
Cancer and Leukemia Group B

Completed

Phase III Comparison of Adjuvant Chemotherapy W/High-Dose Cyclophosphamide Plus Doxorubicin (AC) vs Sequential Doxorubicin Fol by Cyclophosphamide (A-C) in High Risk Breast Cancer Patients With 0-3 Positive Nodes (Intergroup, CALGB 9394)

Breast Cancer | High Risk | Cyclophosphamide | Positive Nodes | Doxorubicin

United States
Fondazione Sandro Pitigliani

Completed

To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy (TREnd)

Breast Cancer

Italy
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer

Inflammatory Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage IIIB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer

Stage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer

United States
Ottawa Hospital Research Institute

Unknown

The EMPOwER Study Evaluating Multiparameter Gene Testing as a Predictor of Short Term Endocrine Therapy Response in Hormone Receptor Positive Breast Cancers (OTT 17-01)

Breast Cancer
Zhejiang Cancer Hospital

Unknown

Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer

Breast Cancer

China
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3)

Breast Cancer
Novartis Pharmaceuticals

Completed

Everolimus in Combination With Exemestane in the Treatment of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer Who Are Refractory to Letrozole or Anastrozole (BOLERO-2)

Breast Cancer

United States, Belgium, Canada, France, Spain, Turkey, Japan, Egypt, Germany, Austria, Poland, Sweden, United Kingdom, Thailand, Hungary, Australia, Italy, Netherlands, Brazil, Hong Kong, Czech Republic, Korea, Republic of, New Zealand and more
Samsung Medical Center
Asan Medical Center; Seoul National University Hospital; Ulsan University Hospital and other collaborators

Unknown

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (FLAG)

Metastatic Breast Cancer | Estrogen Receptor Positive Tumor | Breast Cancer Nos Premenopausal

Korea, Republic of
Samsung Medical Center

Completed

Usefulness of Ki67 Index in Hormone Receptor-positive Breast Cancer

Breast Cancer

Korea, Republic of
University of Washington
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Stage IV Hormone Receptor Positive Breast Cancer

HER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Recurrent Breast Cancer

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0927:Omega3-Fatty Acid Supp in Treating Muscle&Bone Pain&Stiffness in Pts W/Stg I,II,III Brst Canc Rec'v Hormone Thpy

Pain | Breast Cancer | Arthralgia

United States
Massachusetts General Hospital
Novartis; Dana-Farber Cancer Institute

Terminated

Intermittent Letrozole Therapy in Postmenopausal Women With Metastatic Breast Cancer

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer

Breast Cancer

France
Novartis Pharmaceuticals

Completed

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer

Breast Cancer

Germany
Novartis Pharmaceuticals

Completed

4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast Cancer (MACS2096)

Metastatic Breast Cancer

Germany
Novartis Pharmaceuticals

Completed

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer

United States
Stanford University
AstraZeneca

Terminated

Phase 2 Anastrozole and Vandetanib (ZD6474) in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

Breast Cancer

United States
Yale University

Completed

Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial

Breast Cancer

United States
Emory University
Novartis

Terminated

Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer

Mucositis | Stage III Renal Cell Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Gastrinoma | Glucagonoma | Insulinoma | Pancreatic Polypeptide Tumor | Recurrent Islet Cell Carcinoma | Somatostatinoma | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer | Stage IIIC Breast... and other conditions

United States
Cancer Research UK

Completed

Abiraterone Acetate in Treating Postmenopausal Women With Advanced or Metastatic Breast Cancer

Breast Cancer

United Kingdom
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
PersonGen BioTherapeutics (Suzhou) Co., Ltd.
The First People's Hospital of Hefei; Hefei Binhu Hospital

Unknown

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

Hepatocellular Carcinoma | Malignant Glioma of Brain | Non-small Cell Lung Cancer | Gastric Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma | Triple-Negative Invasive Breast Carcinoma

China
Genzyme, a Sanofi Company

Terminated

ZACtima FASlodex Trial in Postmenopausal Advance Breast Cancer Patients Instead of ZACtima FASlodex Trial (ZACFAST)

Breast Cancer

Italy
Peking Union Medical College Hospital

Unknown

Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer (AETNBC)

Female Breast Cancer

China
NantCell, Inc.

Completed

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Metastatic Cancer | Breast Tumors

United States, France, Canada, United Kingdom, Spain, Australia, Germany, Ireland, Switzerland
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

Sarcoma | Glioblastoma | Recurrent Ovarian Carcinoma | Recurrent Uterine Corpus Carcinoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Metastatic Renal Cell Cancer | Recurrent Lung Carcinoma | Recurrent Renal Cell Carcinoma | Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage... and other conditions

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer

Breast Cancer

United States
KU Leuven
Novartis

Unknown

Investigating Patient Satisfaction With Oral Anti-cancer Treatment in Patients With Hormone-receptor Positive, HER2-receptor Negative, Advanced Breast Cancer (IPSOC-mamma)

ER Positive, HER2 Negative Breast Cancer Neoplasms

Belgium
International Breast Cancer Research Foundation
Breast Cancer Research Foundation

Completed

Luteal vs Follicular Surgical Oophorectomy and Tamoxifen in Premenopausal Women With Metastatic Hormone Receptor Positive Breast Cancer

Breast Cancer

United States, China, Bangladesh, Nigeria, Philippines, Morocco, India, Indonesia, Malaysia, Vietnam
Virginia Commonwealth University
National Cancer Institute (NCI)

Completed

Hormone Therapy Or Chemotherapy Before Surgery Based on Gene Expression Analysis in Treating Patients With Breast Cancer

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ

United States, Canada
University of Michigan Rogel Cancer Center

Completed

Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer (LOGRIBMET)

Obesity | Breast Cancer | Arthralgia

United States
National University Hospital, Singapore

Unknown

Prospective Study of UDP-gluconoryltransferase 2B17 Genotype as a Predictive Marker of Exemestane PK and PD

Breast Carcinoma

Singapore
Consorzio Oncotech
Clinical Research Technology S.r.l.

Unknown

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer (FEVEX)

Breast Cancer | Metastatic Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Locally Advanced Malignant Neoplasm

Italy
Bristol-Myers Squibb
US Oncology Research

Completed

Randomized Phase II Trial of Letrozole With or Without Dasatinib as First and Second-line Treatment for Hormone Receptor-positive, HER2-negative Post-menopausal Breast Cancer That is Unresectable, Locally Recurrent or Metastatic

Metastatic Breast Cancer

United States
Sanofi

Completed

Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer

Breast Cancer

United States, France, Spain
Bristol-Myers Squibb

Completed

Randomized Trial of Fulvestrant With or Without Dasatinib in Men and Postmenopausal Women Who Have Hormone Receptor-positive Advanced Breast Cancer Previously Treated With an Aromatase Inhibitor

Advanced Breast Cancer

United States
Merrimack Pharmaceuticals

Completed

Trial of Exemestane +/- MM-121 in Postmenopausal Women With Locally Advanced or Metastatic Estrogen Receptor Positive and/or Progesterone Receptor Positive Her2 Negative Breast Cancer

Her2 Negative Breast Cancer Patients

United States, Spain, Canada, Germany, Russian Federation
Mahidol University

Completed

Effect of Inhaled Mometasone/Formoterol Versus Inhaled Fluticasone/Salmeterol in Asthma Patients

Asthma

Thailand

Search clinical trials for: hormone receptor positive breast cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations